Clinical Trials Using Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102

Clinical trials are research studies that involve people. The clinical trials on this list are studying Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-15 of 15
  • Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients with Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

    This phase I trial studies the side effects and best dose of trametinib and trifluridine and tipiracil hydrochloride in treating patients with colon or rectal cancer that has spread to other places in the body (advanced / metastatic) or cannot be removed by surgery. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as trifluridine and tipiracil hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trametinib and trifluridine and tipiracil hydrochloride may prevent cancer cells from dividing and work better in treating patients with colon and rectal cancer.
    Location: 8 locations

  • TAS102 and Liposomal Irinotecan in Treating Patients with Gastrointestinal Cancers That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

    This phase I / II trial studies the best dose and how well trifluridine / tipiracil hydrochloride combination agent TAS-102 (TAS-102) and liposomal irinotecan work in treating patients with gastrointestinal cancers that have spread to other places in the body (metastatic) or cannot be removed by surgery. Drugs used in the chemotherapy, such as trifluridine / tipiracil hydrochloride combination agent TAS-102 and liposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 3 locations

  • First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine / Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors

    Study HS-CA102N-101 is a phase 1, two part (dose escalation, dose expansion), multicenter, non-randomized, open-label, multiple dose, first-in-human study of CA102N monotherapy and of CA102N combined with trifluridine / tipiracil (LONSURF) in subjects with advanced solid tumors. CA102N will be evaluated in subjects with locally advanced or metastatic solid tumours for which no effective therapy is available in Part 1 (dose escalation) and in subjects with relapsed or refractory locally advanced or metastatic colorectal cancer (mCRC) after prior oxaliplatin and irinotecan-based chemotherapy in Part 2 (dose expansion).
    Location: 2 locations

  • TAS-102 and Radiation Therapy in Treating Patients with Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery

    This phase I trial studies the side effects and best dose of trifluridine and tipiracil hydrochloride (TAS-102) when given together with radiation therapy in treating patients with rectal cancer that has come back, spread to other places in the body, or cannot be removed by surgery. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving TAS-102 with radiation therapy may kill more tumor cells.
    Location: 2 locations

  • Lonsurf, Gemcitabine, and Nab-Paclitaxel in Treating Patients with Advanced Pancreatic Ductal Adenocarcinoma

    This phase I trial studies the best dose of Lonsurf, gemcitabine, and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Drugs used in chemotherapy, such as Lonsurf, gemcitabine, and nab-paclitaxel, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

  • Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients with Advanced or Metastatic Colorectal Cancer

    This phase II trial studies circulating cell-free tumor DNA testing to guide treatment with regorafenib or TAS-102 in patients with colorectal cancer that has spread to other areas of the body. Studying samples of blood from patients with colorectal cancer may help doctors understand how well patients respond to treatment. Regorafenib and TAS-102 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known how well ctDNA testing works in guiding treatment with regorafenib and TAS-102 for patients with advanced or metastatic colorectal cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • TAS 102 and Ramucirumab in Treating Patients with Stage IV or Recurrent Gastric or Gastroesophageal Junction Cancer

    This phase II trial studies the side effects and how well TAS 102 and ramucirumab work in treating patients with gastric or gastroesophageal junction cancer that is stage IV or that has come back. TAS 102 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ramucirumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving TAS 102 and ramucirumab may work better in treating patients with gastric or gastroesophageal junction cancer.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Trifluridine and Tipiracil Hydrochloride and Stereotactic Body Radiation Therapy in Treating Patients with Colorectal Cancer with Liver Metastases

    This phase Ib / II trial studies the side effects and best dose of trifluridine and tipiracil hydrochloride when given together with stereotactic body radiation therapy and how well they work in treating patients with colorectal cancer that has spread to the liver. Trifluridine and tipiracil hydrochloride stops deoxyribonucleic acid (DNA) replication which may prevent cancer cells from growing. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving trifluridine and tipiracil hydrochloride and stereotactic body radiation therapy may work better in treating patients with colorectal cancer that has spread to the liver.
    Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts

  • TAS-102 and Temozolomide in Treating Patients with Metastatic Neuroendocrine Tumors

    This phase IB trial studies the side effects and best dose of temozolomide when given together with trifluridine and tipiracil hydrochloride (TAS-102) and to see how well they work in treating patients with neuroendocrine tumors that have spread to other places in the body. Drugs used in chemotherapy, such as TAS-102 and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin

  • TAS-102 and Oxaliplatin in Treating Patients with Refractory Stage IV Colon or Colorectal Cancer

    This phase IB / II trial studies the side effects and best dose of trifluridine and tipiracil hydrochloride (TAS-102) when given together with oxaliplatin and to see how well it works in treating patients with stage IV colon or colorectal cancer that does not respond to treatment. TAS-102 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving TAS-102 and oxaliplatin may work better in treating patients with colon or colorectal cancer.
    Location: Yale University, New Haven, Connecticut

  • TAS-102 and Yttrium-90 Microsphere Radioembolization in Treating Patients with Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

    This phase I trial studies the side effect and best dose of trifluridine / tipiracil hydrochloride combination agent TAS-102 (TAS-102) and to see how well it works when given together with Yttrium-90 microsphere radioembolization in treating patients with colorectal cancer that has spread to other places in the body and cannot be removed by surgery. Drugs used in the chemotherapy, such as trifluridine / tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemoembolization kills tumor cells by carrying drugs directly into blood vessels near tumors and then blocking the blood flow to allow a higher concentration of the drug to reach the tumor for a longer period of time. Chemoembolization may cause fewer side effects in treating patients with colorectal cancer. Giving trifluridine / tipiracil hydrochloride combination agent TAS-102 and Yttrium-90 microsphere radioembolization may work better in treating patients with colorectal cancer.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

    Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.
    Location: 2 locations

  • Panitumumab, Regorafenib, or TAS-102, in Treating Patients with Metastatic and / or Unresectable RAS Wild-Type Colorectal Cancer

    This phase II trial studies how well retreatment with panitumumab works compared to standard of care regorafenib or trifluridine and tipiracil hydrochloride (TAS-102) in treating patients with colorectal cancer that is negative for RAS wild-type colorectal cancer has spread to other places in the body, and / or cannot be removed by surgery, and is negative for resistance mutations in blood. Treatment with panitumumab may interfere with the ability of tumor cells to grow and spread. Some tumors need growth factors to keep growing. Growth factor antagonists, such as regorafenib, may interfere with the growth factor and stop the tumor from growing. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving panitumumab may work better in treating patients with colorectal cancer than with the usual treatment of regorafenib or TAS-102.
    Location: 6 locations

  • Binimetinib and Palbociclib or TAS-102 in Treating Patients with KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

    This phase II trial studies how well binimetinib and palbociclib work compared to TAS-102 in treating patients with KRAS and NRAS mutation positive colorectal cancer that has spread to other places in the body or cannot be removed by surgery. Binimetinib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving binimetinib and palbociclib may work better compared to TAS-102 alone in treating patients with colorectal cancer.
    Location: 8 locations

  • TAS-102 in Treating Patients with Locally Advanced Unresectable or Metastatic Bladder Cancer

    This phase II trial studies how well TAS-102 works in treating patients with bladder cancer that has spread to nearby tissue, lymph nodes, or other places in the body and cannot be removed by surgery. TAS-102 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Kansas Cancer Center, Kansas City, Kansas